Indianapolis, Indiana, United States The fund was located in North America if to be more exact in United States. The main department of described VC is located in the Indianapolis.
The fund is generally included in less than 2 deals every year. The typical startup value when the investment from BioCrossroads is 1-5 millions dollars. The real fund results show that this VC is 6 percentage points less often commits exit comparing to other companies. The usual things for fund are deals in the range of 1 - 5 millions dollars. The important activity for fund was in 2013.
The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the BioCrossroads, startups are often financed by National Institutes of Health, Elevate Ventures, Don Brown. The meaningful sponsors for the fund in investment in the same round are StepStone Angels, Spring Mill Venture Partners, Queen City Angels. In the next rounds fund is usually obtained by Triathlon Medical Venture Partners, Spring Mill Venture Partners, Prolog Ventures.
Among the most successful fund investment fields, there are Biotechnology, Diabetes. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight FlowCo, SpeechVive, Scioto Biosciences. The fund has specific favorite in a number of founders of portfolio startups. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Baisheng Xinda | China, Qingpu, Shanghai |
| Bull Partners | Community of Madrid, Madrid, Spain |
| Capital Emprendedor | Houston, Texas, United States |
| DreamFunded | California, San Francisco, United States |
| Equitas Capital Advisors | Louisiana, New Orleans, United States |
| Fides Capital partners | Illinois, Lake Forest, United States |
| Hong Kong Yihe | China, Hong Kong, Hong Kong Island |
| Hyundai Investment Partners | Seoul, Seoul-t'ukpyolsi, South Korea |
| Intersect Partners LLC. | Incline Village, Nevada, United States |
| Link Group | Australia, New South Wales, Sydney |
| MobiKwik | Gurgaon, Haryana, India |
| Momentum Investment Group | Australia, Melbourne, Victoria |
| Mosaic Asset Management | Irving, Texas, United States |
| PaRan GongCheng | Beijing, Beijing, China |
| Puheng Touzi | China, Jiangsu, Nanjing |
| Ronald Lauder Ventures | - |
| Stocktwits | New York, New York, United States |
| Sunfish Partners | Mazowieckie, Poland, Warsaw |
| West Japan Railway | Japan, Osaka, Osaka Prefecture |
| Zhonghui Hongcheng Touzi | Beijing, Beijing, China |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Kovina Therapeutics | $2M | 20 Oct 2021 | Indianapolis, Indiana, United States | ||
Novosteo | $5M | 13 Jan 2021 | Pennsylvania, United States | ||
MBX Biosciences | $34M | 27 Jul 2020 | Indiana, United States | ||
Sabanto | $2M | 12 Aug 2019 | Chicago, Illinois, United States | ||
Scioto Biosciences | $1M | 21 May 2018 | Indianapolis, Indiana, United States | ||
SonarMed | $3M | 24 Oct 2017 | Indianapolis, Indiana, United States | ||
Allinaire Therapeutics | $1M | 27 Jan 2017 | Cleveland, Ohio, United States | ||
SpeechVive | $975K | 18 May 2016 | Lafayette, Indiana, United States | ||
Diagnotes | $1M | 25 Apr 2013 | Indianapolis, Indiana, United States |
– Novosteo Closes $5.5m in Series A Financing.
– The company raised $5.5m in Series A financing.
– The round was led by Kairos Ventures, as well as BioCrossroads Ventures, Elevate Ventures and Purdue Research Foundation.
– Proceeds from the financing will be used to advance NOV004 into clinical development that will begin in the first half of 2021.
– Research Bridge Partners announced that one of its portfolio companies, Novosteo, Inc., closed $5.5m in Series A financing to further development of the first-ever targeted bone anabolic agent NOV004.
– The round was led by Kairos Ventures, as well as BioCrossroads Ventures, Elevate Ventures and Purdue Research Foundation.
– Novosteo, Inc.’s NOV004 has shown promise in live animals in the acceleration of fracture healing when delivered systemically.
– Proceeds from the financing will be used to advance NOV004 into clinical development that will begin in the first half of 2021.
– Bone injuries and disease are one of the most challenging health issues facing all ages, especially for the elderly.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Kovina Therapeutics | $2M | 20 Oct 2021 | Indianapolis, Indiana, United States | ||
Novosteo | $5M | 13 Jan 2021 | Pennsylvania, United States | ||
MBX Biosciences | $34M | 27 Jul 2020 | Indiana, United States | ||
Sabanto | $2M | 12 Aug 2019 | Chicago, Illinois, United States | ||
Scioto Biosciences | $1M | 21 May 2018 | Indianapolis, Indiana, United States | ||
SonarMed | $3M | 24 Oct 2017 | Indianapolis, Indiana, United States | ||
Allinaire Therapeutics | $1M | 27 Jan 2017 | Cleveland, Ohio, United States | ||
SpeechVive | $975K | 18 May 2016 | Lafayette, Indiana, United States | ||
Diagnotes | $1M | 25 Apr 2013 | Indianapolis, Indiana, United States |
